Data presented at 2027 ASMBS meeting showed betw 2020-2024, wt loss surgeries dropped 23%, from 230,000 in 2022 to 177,000 in 2024. Less than 1% of eligible pts are now having weight-loss surgery https://t.co/UnYIIBDdnz https://t.co/FuwnOuBUeY

• Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Expert…

Weight Loss Improves Psoriatic Disease Substantially! Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent https://t.co/BWeW7fzSC8

A Day of Infamy (9.11.2026) Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. https://t.co/gzaqNz3i5k https://t.co/c8ShScutqC

• A Day of Infamy (9.11.2026) | RheumNow

Metanalysis 11 studies & 104277 gout & hyperuricemic pts shows erectile dysfunction is signif. increased (RR1.37; 1.14-1.65) related to lower testosterone & estradiol. Other factors: obesity, age, DM, CVD. https://t.co/1ufih2E3UN https://t.co/NgQuHt4vR1

• Frontiers | Gout, hyperuricemia, and male reproductive health: a systematic rev…

Congratulations to Professor Christopher Goodnow, BVSc, MBBS, PhD (from UNSW Sydney) as he is the recipient of the German Paul Ehrlich and Ludwig Darmstaedter Prize for 2027 base on his work in autoimmunity! https://t.co/uvfYfXTrh3 https://t.co/FgyOzTI8lb

• Christopher Goodnow to eceive the 2027 Paul Ehrlich and Ludwig Darmstaedter Pri…

Single center study of FALLs in 124 ambulatory RA females ≥50 yrs.(age 68 yrs, DAS28 2.6, sarcopenia 16%, prior fall 25%). 27.4% had falls; predicted by prior fall hx (OR 2.76, hypnotics/anxiolytics (3.92), not steroids or sarcopenia (NS trend) https://t.co/J62RPF9rQs https://t.co/OKxdPl5Oev

• https://buff.ly/wRfK20U

Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy https://t.co/5MPm388kau

• https://buff.ly/6ZIzPu2

In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD https://t.co/aeB5N6LgCd

• Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022:…

JAMA: Review of Adult Rheumatoid Arthritis This JAMA narrative review is a follow-up to their 2018 publication, informed by 123 articles (46 RCTs, 28 cohort studies, 11 systematic reviews/meta-analyses, 15 guidelines) covering epidemiology, pathogenesis, diagnosis, and https://t.co/6Fiu9iLF5I

Obesity in Axial Spondyloarthritis: what are we missing beyond the scale? Obesity in axSpA is not a minor comorbidity. While obesity is more often discussed in psoriatic arthritis (PsA) due to the psoriasis-adipose tissue link which is mechanistically better studied and https://t.co/bFkoPmc0pC

FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw https://t.co/evzPtaTWI4

• FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis | Patient Care O…